特利加压素联合白蛋白治疗肝肾综合征效果的预测因素

曹倩玫; 梅浙川

doi:10.3969/j.issn.1001-5256.2021.10.038

特利加压素联合白蛋白治疗肝肾综合征效果的预测因素

DOI: 10.3969/j.issn.1001-5256.2021.10.038

曹倩玫,
梅浙川^,

重庆医科大学附属第二医院消化科, 重庆 400010

详细信息

通信作者:
梅浙川，meizhechuan@cqmu.edu.cn

中图分类号: R575.2
计量
- 文章访问数: 537
- HTML全文浏览量: 222
- PDF下载量: 50
- 被引次数: 0
出版历程
- 收稿日期: 2021-03-01
- 录用日期: 2021-03-15
- 出版日期: 2021-10-20

Predictive factors for the therapeutic effect of terlipressin combined with albumin in hepatorenal syndrome

Qianmei CAO,
Zhechuan MEI^,

Department of Gastroenterology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing 400010, China

摘要

摘要: 肝肾综合征(HRS)是终末期肝病的严重并发症，主要发生于有明显循环功能障碍的晚期肝硬化患者，预后较差。目前首选的药物治疗方案是特利加压素联合白蛋白治疗。关于特利加压素联合白蛋白治疗效果的预测因素的研究较多，但尚未有相关综合报道。从HRS的发病机制和药物作用机制方面回顾了这一疾病的最新研究进展，从基线资料、治疗后变化及治疗方案等方面对特利加压素联合白蛋白治疗效果的预测因素的研究进展进行了综述，指出早期识别有助于预测治疗反应的因素具有重要的临床意义。
- 肝硬化 /
- 肝肾综合征 /
- 治疗结果
Abstract: Hepatorenal syndrome (HRS) is a serious complication of end-stage liver disease often observed in advanced liver cirrhosis patients with circulatory dysfunction and tends to have poor prognosis. At present, terlipressin combined with albumin is the preferred drug treatment regimen for HRS. Many studies have been conducted on the predictive factors for the therapeutic effect of terlipressin combined with albumin, but there lacks a comprehensive report of these studies. This article reviews the latest research advances in this disease and its treatment from the pathogenesis of HRS and the mechanism of action of drugs, as well as the research advances in the predictive factors for the therapeutic effect of terlipressin combined with albumin in terms of baseline data, changes after treatment, and treatment regimens. It is pointed out that early identification of factors that can help predict treatment response has important clinical significance.
- Liver Cirrhosis /
- Hepatorenal Syndrome /
- Treatment Outcome

HTML全文

参考文献(50)

[1]	ANGELI P, GINÈS P, WONG F, et al. Diagnosis and management of acute kidney injury in patients with cirrhosis: Revised consensus recommendations of the International Club of Ascites[J]. J Hepatol, 2015, 62(4): 968-974. DOI: 10.1016/j.jhep.2014.12.029.
[2]	RICE JP, SKAGEN C, SAID A. Liver transplant outcomes for patients with hepatorenal syndrome treated with pretransplant vasoconstrictors and albumin[J]. Transplantation, 2011, 91(10): 1141-1147. DOI: 10.1097/TP.0b013e31821690bf.
[3]	SALERNO F, CAZZANIGA M, MERLI M, et al. Diagnosis, treatment and survival of patients with hepatorenal syndrome: A survey on daily medical practice[J]. J Hepatol, 2011, 55(6): 1241-1248. DOI: 10.1016/j.jhep.2011.03.012.
[4]	SALERNO F, GERBES A, GINÀS P, et al. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis[J]. Gut, 2007, 56(9): 1310-1318. DOI: 10.1136/gut.2006.107789.
[5]	SALERNO F, NAVICKIS RJ, WILKES MM. Albumin treatment regimen for type 1 hepatorenal syndrome: A dose-response meta-analysis[J]. BMC Gastroenterol, 2015, 15: 167. DOI: 10.1186/s12876-015-0389-9.
[6]	WONG F. Recent advances in our understanding of hepatorenal syndrome[J]. Nat Rev Gastroenterol Hepatol, 2012, 9(7): 382-391. DOI: 10.1038/nrgastro.2012.96.
[7]	FERNANDEZ-SEARA J, PRIETO J, QUIROGA J, et al. Systemic and regional hemodynamics in patients with liver cirrhosis and ascites with and without functional renal failure[J]. Gastroenterology, 1989, 97(5): 1304-1312. DOI: 10.1016/0016-5085(89)91704-6.
[8]	SOLÀ E, GINÈS P. Renal and circulatory dysfunction in cirrhosis: Current management and future perspectives[J]. J Hepatol, 2010, 53(6): 1135-1145. DOI: 10.1016/j.jhep.2010.08.001.
[9]	CHUANG CL, CHANG CC, HSU SJ, et al. Endotoxemia-enhanced renal vascular reactivity to endothelin-1 in cirrhotic rats[J]. Am J Physiol Gastrointest Liver Physiol, 2018, 315(5): g752-g761. DOI: 10.1152/ajpgi.00302.2017.
[10]	KRAG A, GLUUD LL. Cross-talk between the liver, heart and kidney - another piece in the puzzle[J]. J Gastrointestin Liver Dis, 2014, 23(2): 119-121. DOI: 10.15403/jgld.2014.1121.ak1.
[11]	KRAG A, BENDTSEN F, HENRIKSEN JH, et al. Low cardiac output predicts development of hepatorenal syndrome and survival in patients with cirrhosis and ascites[J]. Gut, 2010, 59(1): 105-110. DOI: 10.1136/gut.2009.180570.
[12]	VELEZ J, THERAPONDOS G, JUNCOS LA. Reappraising the spectrum of AKI and hepatorenal syndrome in patients with cirrhosis[J]. Nat Rev Nephrol, 2020, 16(3): 137-155. DOI: 10.1038/s41581-019-0218-4.
[13]	ACEVEDO J, FERNÁNDEZ J, PRADO V, et al. Relative adrenal insufficiency in decompensated cirrhosis: Relationship to short-term risk of severe sepsis, hepatorenal syndrome, and death[J]. Hepatology, 2013, 58(5): 1757-1765. DOI: 10.1002/hep.26535.
[14]	THABUT D, MASSARD J, GANGLOFF A, et al. Model for end-stage liver disease score and systemic inflammatory response are major prognostic factors in patients with cirrhosis and acute functional renal failure[J]. Hepatology, 2007, 46(6): 1872-1882. DOI: 10.1002/hep.21920.
[15]	HAMPEL H, BYNUM GD, ZAMORA E, et al. Risk factors for the development of renal dysfunction in hospitalized patients with cirrhosis[J]. Am J Gastroenterol, 2001, 96(7): 2206-2210. DOI: 10.1111/j.1572-0241.2001.03958.x.
[16]	LANG F, TSCHERNKO E, SCHULZE E, et al. Hepatorenal reflex regulating kidney function[J]. Hepatology, 1991, 14(4 Pt 1): 590-594. DOI: 10.1016/0270-9139(91)90043-u.
[17]	SOLANKI P, CHAWLA A, GARG R, et al. Beneficial effects of terlipressin in hepatorenal syndrome: A prospective, randomized placebo-controlled clinical trial[J]. J Gastroenterol Hepatol, 2003, 18(2): 152-156. DOI: 10.1046/j.1440-1746.2003.02934.x.
[18]	NARAHARA Y, KANAZAWA H, TAKI Y, et al. Effects of terlipressin on systemic, hepatic and renal hemodynamics in patients with cirrhosis[J]. J Gastroenterol Hepatol, 2009, 24(11): 1791-1797. DOI: 10.1111/j.1440-1746.2009.05873.x.
[19]	ALESSANDRIA C, OTTOBRELLI A, DEBERNARDI-VENON W, et al. Noradrenalin vs terlipressin in patients with hepatorenal syndrome: A prospective, randomized, unblinded, pilot study[J]. J Hepatol, 2007, 47(4): 499-505. DOI: 10.1016/j.jhep.2007.04.010.
[20]	WONG F, PAPPAS SC, BOYER TD, et al. Terlipressin improves renal function and reverses hepatorenal syndrome in patients with systemic inflammatory response syndrome[J]. Clin Gastroenterol Hepatol, 2017, 15(2): 266-272. e1. DOI: 10.1016/j.cgh.2016.07.016.
[21]	GARCIA-MARTINEZ R, CARACENI P, BERNARDI M, et al. Albumin: Pathophysiologic basis of its role in the treatment of cirrhosis and its complications[J]. Hepatology, 2013, 58(5): 1836-1846. DOI: 10.1002/hep.26338.
[22]	UMGELTER A, WAGNER KS, REINDL W, et al. Renal and circulatory effects of large volume plasma expansion in patients with hepatorenal syndrome type 1[J]. Ann Hepatol, 2012, 11(2): 232-239.
[23]	BRINCH K, MØLLER S, BENDTSEN F, et al. Plasma volume expansion by albumin in cirrhosis. Relation to blood volume distribution, arterial compliance and severity of disease[J]. J Hepatol, 2003, 39(1): 24-31. DOI: 10.1016/s0168-8278(03)00160-0.
[24]	GLUUD LL, CHRISTENSEN K, CHRISTENSEN E, et al. Systematic review of randomized trials on vasoconstrictor drugs for hepatorenal syndrome[J]. Hepatology, 2010, 51(2): 576-584. DOI: 10.1002/hep.23286.
[25]	HINZ M, WREE A, JOCHUM C, et al. High age and low sodium urine concentration are associated with poor survival in patients with hepatorenal syndrome[J]. Ann Hepatol, 2013, 12(1): 92-99.
[26]	TESTRO AG, WONGSEELASHOTE S, ANGUS PW, et al. Long-term outcome of patients treated with terlipressin for types 1 and 2 hepatorenal syndrome[J]. J Gastroenterol Hepatol, 2008, 23(10): 1535-1540. DOI: 10.1111/j.1440-1746.2007.05176.x.
[27]	SHARMA P, KUMAR A, SHRAMA BC, et al. An open label, pilot, randomized controlled trial of noradrenaline versus terlipressin in the treatment of type 1 hepatorenal syndrome and predictors of response[J]. Am J Gastroenterol, 2008, 103(7): 1689-1697. DOI: 10.1111/j.1572-0241.2008.01828.x.
[28]	RODRÍGUEZ E, ELIA C, SOLÀ E, et al. Terlipressin and albumin for type-1 hepatorenal syndrome associated with sepsis[J]. J Hepatol, 2014, 60(5): 955-961. DOI: 10.1016/j.jhep.2013.12.032.
[29]	GHOSH S, CHOUDHARY NS, SHARMA AK, et al. Noradrenaline vs terlipressin in the treatment of type 2 hepatorenal syndrome: A randomized pilot study[J]. Liver Int, 2013, 33(8): 1187-1193. DOI: 10.1111/liv.12179.
[30]	MARTÍN-LLAHÍ M, PÉPIN MN, GUEVARA M, et al. Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: A randomized study[J]. Gastroenterology, 2008, 134(5): 1352-1359. DOI: 10.1053/j.gastro.2008.02.024.
[31]	SANYAL AJ, BOYER T, GARCIA-TSAO G, et al. A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome[J]. Gastroenterology, 2008, 134(5): 1360-1368. DOI: 10.1053/j.gastro.2008.02.014.
[32]	SARWAR S, KHAN AA. Hepatorenal syndrome: Response to terlipressin and albumin and its determinants[J]. Pak J Med Sci, 2016, 32(2): 274-278. DOI: 10.12669/pjms.322.9315.
[33]	BOYER TD, SANYAL AJ, GARCIA-TSAO G, et al. Predictors of response to terlipressin plus albumin in hepatorenal syndrome (HRS) type 1: Relationship of serum creatinine to hemodynamics[J]. J Hepatol, 2011, 55(2): 315-321. DOI: 10.1016/j.jhep.2010.11.020.
[34]	NAZAR A, PEREIRA GH, GUEVARA M, et al. Predictors of response to therapy with terlipressin and albumin in patients with cirrhosis and type 1 hepatorenal syndrome[J]. Hepatology, 2010, 51(1): 219-226. DOI: 10.1002/hep.23283.
[35]	ABDEL-RAZIK A, MOUSA N, ABDELSALAM M, et al. Endothelin-1/nitric oxide ratio as a predictive factor of response to therapy with terlipressin and albumin in patients with type-1 hepatorenal syndrome[J]. Front Pharmacol, 2020, 11: 9. DOI: 10.3389/fphar.2020.00009.
[36]	HEIDEMANN J, BARTELS C, BERSSENBRVGGE C, et al. Hepatorenal syndrome: Outcome of response to therapy and predictors of survival[J]. Gastroenterol Res Pract, 2015, 2015: 457613. DOI: 10.1155/2015/457613.
[37]	ALLEGRETTI A, PARADA X, ENDRES P, et al. Urinary NGAL as a diagnostic and prognostic marker for acute kidney injury in cirrhosis: A prospective study[J]. Clin Transl Gastroenterol, 2021, 12(5): e00359. DOI: 10.14309/ctg.0000000000000359.
[38]	APPENRODT B, ZIELINSKI J, BRENSING KA, et al. Degree of hepatic dysfunction and improvement of renal function predict survival in patients with HRS type I: A retrospective analysis[J]. Eur J Gastroenterol Hepatol, 2009, 21(12): 1428-1432. DOI: 10.1097/MEG.0b013e32832ec16a.
[39]	SINGH V, GHOSH S, SINGH B, et al. Noradrenaline vs. terlipressin in the treatment of hepatorenal syndrome: A randomized study[J]. J Hepatol, 2012, 56(6): 1293-1298. DOI: 10.1016/j.jhep.2012.01.012.
[40]	CAVALLIN M, PIANO S, ROMANO A, et al. Terlipressin given by continuous intravenous infusion versus intravenous boluses in the treatment of hepatorenal syndrome: A randomized controlled study[J]. Hepatology, 2016, 63(3): 983-992. DOI: 10.1002/hep.28396.
[41]	von KALCKREUTH V, GLOWA F, GEIBLER M, et al. Terlipressin in 30 patients with hepatorenal syndrome: Results of a retrospective study[J]. Z Gastroenterol, 2009, 47(1): 21-26. DOI: 10.1055/s-0028-1109084.
[42]	PIANO S, MORANDO F, FASOLATO S, et al. Continuous recurrence of type 1 hepatorenal syndrome and long-term treatment with terlipressin and albumin: A new exception to MELD score in the allocation system to liver transplantation?[J]. J Hepatol, 2011, 55(2): 491-496. DOI: 10.1016/j.jhep.2011.02.002.
[43]	WONG F, PAPPAS SC, BOYER TD, et al. Terlipressin improves renal function and reverses hepatorenal syndrome in patients with systemic inflammatory response syndrome[J]. Clin Gastroenterol Hepatol, 2017, 15(2): 266-272. e1. DOI: 10.1016/j.cgh.2016.07.016.
[44]	MOREAU R, BARRIÈRE E, TAZI KA, et al. Terlipressin inhibits in vivo aortic iNOS expression induced by lipopolysaccharide in rats with biliary cirrhosis[J]. Hepatology, 2002, 36(5): 1070-1078. DOI: 10.1053/jhep.2002.36501.
[45]	MADDUKURI G, CAI CX, MUNIGALA S, et al. Targeting an early and substantial increase in mean arterial pressure is critical in the management of type 1 hepatorenal syndrome: A combined retrospective and pilot study[J]. Dig Dis Sci, 2014, 59(2): 471-481. DOI: 10.1007/s10620-013-2899-z.
[46]	VELEZ JC, NIETERT PJ. Therapeutic response to vasoconstrictors in hepatorenal syndrome parallels increase in mean arterial pressure: A pooled analysis of clinical trials[J]. Am J Kidney Dis, 2011, 58(6): 928-938. DOI: 10.1053/j.ajkd.2011.07.017.
[47]	SCHNEIDER AG, SCHELLEMAN A, GOODWIN MD, et al. Contrast-enhanced ultrasound evaluation of the renal microcirculation response to terlipressin in hepato-renal syndrome: A preliminary report[J]. Ren Fail, 2015, 37(1): 175-179. DOI: 10.3109/0886022X.2014.977140.
[48]	MOORE K, WENDON J, FRAZER M, et al. Plasma endothelin immunoreactivity in liver disease and hepatorenal syndrome[J]. N Engl J Med, 1992, 327(25): 1774-1778. DOI: 10.1056/NEJM199212173272502.
[49]	DONG T, ARONSOHN A, GAUTHAM REDDY K, et al. Rifaximin decreases the incidence and severity of acute kidney injury and hepatorenal syndrome in cirrhosis[J]. Dig Dis Sci, 2016, 61(12): 3621-3626. DOI: 10.1007/s10620-016-4313-0.
[50]	KALAMBOKIS GN, MOUZAKI A, RODI M, et al. Rifaximin improves systemic hemodynamics and renal function in patients with alcohol-related cirrhosis and ascites[J]. Clin Gastroenterol Hepatol, 2012, 10(7): 815-818. DOI: 10.1016/j.cgh.2012.02.025.